Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment

Illana Gozes*, Ayelet Reshef, Dalia Salah, Sara Rubinraut, Mati Fridkin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The present report relates to pharmaceutical composition for the treatment of male impotence. The transdermal application of a potent derivative of vasoactive intestinal peptide (VIP) coupled to a suitable hydrophobic moiety (e.g. stearyl-VIP) in a suitable ointment composition (e.g. Sefsol) enhances sexual activity and erection formation in a variety of impotence models in rats (sterile rats, diabetic rats, and animals with high blood pressure). Furthermore, exchange of the methionine in position 17 with norleucine enhances biological activity. Thus, stearyl-Nle17-VIP may be considered useful for the treatment of impotence.

Original languageEnglish
Pages (from-to)2121-2125
Number of pages5
JournalEndocrinology
Volume134
Issue number5
DOIs
StatePublished - May 1994

Fingerprint

Dive into the research topics of 'Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment'. Together they form a unique fingerprint.

Cite this